Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40results about How to "Long persistence" patented technology

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.
Owner:SEQIRUS UK LTD

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.
Owner:SEQIRUS UK LTD

Disinfecting composition based on H2O2, acids and metal ions

The invention concerns an oxidising aqueous composition useful in particular for disinfection, hygiene and depollution purposes, and for surface treatment (particularly a metal surface to be stripped and / or passivated), and said composition, containing in water hydrogen peroxide, a RCO2H / RCO3H mixture (wherein R is a C1-C6 aliphatic radical with linear or branched hydrocarbon chain, saturated or unsaturated), a stabilising agent which is an acid and, as the case may be, Ag<+> ions. The invention is characterised in that it contains ions of at least one metal M which are ions of Ag<II>, Ag<III>, V<V>, Nb<V>, Ta<V>, Mo<VI>, W<VI>, Co<III>, In<III >or Tl<III>. Advantageously, said composition can be in gel form. The invention also concerns the method for preparing said composition.
Owner:DIGOL INT LTD

Micro-electromechanical display backplane and improvements thereof

A low cost, scalable backplane for electrophoretic displays comprising a multi-membrane plastic array of micro electromechanical (MEM) switches. Each switch controls the state of a pixel in the electrophoretic display device. Each switch may be latched to eliminate the need to constantly refresh the device and each switch may function as an enunciator
Owner:SEERTECH CORP

Modified vasoactive intestinal peptides

ActiveUS20110178017A1Increased circulatory half-life and persistenceAltered binding preferenceHormone peptidesPeptide/protein ingredientsDrugHalf-life
The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and / or altered receptor binding profile with respect to unmodified VIP.
Owner:PHASEBIO PHARMA INC

Method for producing an electrochromic device and said electrochromic device

The invention relates to a method for producing electrochromic devices, in particular that having a large working surface area and which does not produce a volumetric shrinkage and can operate during a long maintenance of electrocoloured state of an electrochromic compound, high control voltages and polarity inversion. The inventive electrochromic device comprises at least two electrodes (1, 2), at least one of them being optically transparent. A closed sealed space is formed between said electrodes and filled with the electrochromic compound which is embodied in the form of a solid-like film. The inventive method for producing the electrochromic device consists in prefabricating an initial electrochromic compound in the form of a dispersed electrochromic system which contains at least a suspension and / or colloid. The dispersed medium of said system is embodied in the form of an electrochromic solution containing a liquid solvent, cathode and anode components, a disperse phase being embodied in the form of a finely dispersed polymer. Afterwards, the initial electrochromic compound is deaerated, thereby eliminating dissolved oxygen and air introduced by said finely dispersed polymer, and is used for filling the space between the electrodes.
Owner:AVELUM +1

System and Method Using a Voltage Kick-Off to Record a Hologram on a Photorefractive Polymer for 3D Holographic Display and Other Applications

An updateable system and method of recording a hologram on a media simultaneously reduces the writing time and increases persistence without sacrificing diffraction efficiency. A voltage kick-off technique controls the bias electric field applied to a photorefractive polymer media in conjunction with the application of the writing beams and dark decay. Essentially the voltage kick-off technique applies a high electric field above the optimal field while the writing beams are on and reduces the electric field when the writing beams are off during dark decay. The voltage kick-off technique produced two separate unexpected results. First, when the writing beams are turned off and the electric field is lowered the diffraction efficiency continues to increase until it reaches a maximum efficiency that is within a few percent of that achieved by writing at the optimal field until steady-state is achieved. Second, the decay time constant is much larger than expected producing a much longer persistence without sacrificing diffraction efficiency or writing time.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Modified vasoactive intestinal peptides

ActiveUS9029505B2Increased circulatory half-life and persistenceAltered binding preferencePeptide/protein ingredientsPharmaceutical delivery mechanismHalf-lifeVasoactive intestinal peptide
The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and / or altered receptor binding profile with respect to unmodified VIP.
Owner:PHASEBIO PHARMA INC

Polysaccharide soft tissue fillers with improved persistence

The present invention relates to polysaccharide soft tissue fillers comprising heparosan and processes for their preparation. The polysaccharide soft tissue fillers of the present invention are advantageously used in therapeutic or cosmetic applications such as for the filling of wrinkles.
Owner:MERZ PHARMA GMBH & CO KGAA

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.
Owner:SEQIRUS UK LTD

Use of modified vasoactive intestinal peptides in the treatment of hypertension

The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and / or amelioration of hypertension are provided.
Owner:PHASEBIO PHARMA INC

Liminous phosphor, fluorescent lamp, luminous display, and luminous molded product

There are provided a long persistent phosphor capable of keeping high persistent intensity and white persistence of especially satisfactory color purity after the phosphor is excited by ultraviolet irradiation and then the excited light is cut off, and a fluorescent lamp, a display item of long persistence and a formed product of long persistence in which the phosphor is used.A long phosphorescence persistent phosphor which comprises a mixture or mutual deposit of the first phosphor emitting long persistence in the first wave range by ultraviolet absorption, which is one or more than two of the following phosphors (i) and (ii), and a second phosphor which is excited by at least a part of emission of the first phosphor.Magnesium-strontium silicate phosphor (i) prepared by co-activating a complex-oxide containing Sr, Mg and Si as a matrix metal component with Eu and Dy.Strontium-aluminum silicate phosphor (ii) prepared by co-activating a complex-oxide containing Sr, Al and Si as a matrix metal component with europium Eu and Dy.The long persistent phosphor is used as a fluorescent screen to prepare a fluorescent lamp, applied to a displaying part to prepare a display item of long persistence or added to plastics and other materials and formed into a desired shape to prepare a formed product.
Owner:MITSUBISHI CHEM CORP

Method for producing an electrochromic device and said electrochromic device

The invention relates to a method for producing electrochromic devices, in particular that having a large working surface area and which does not produce a volumetric shrinkage and can operate during a long maintenance of electrocoloured state of an electrochromic compound, high control voltages and polarity inversion. The inventive electrochromic device comprises at least two electrodes (1, 2), at least one of them being optically transparent. A closed sealed space is formed between said electrodes and filled with the electrochromic compound which is embodied in the form of a solid-like film. The inventive method for producing the electrochromic device consists in prefabricating an initial electrochromic compound in the form of a dispersed electrochromic system which contains at least a suspension and / or colloid. The dispersed medium of said system is embodied in the form of an electrochromic solution containing a liquid solvent, cathode and anode components, a disperse phase being embodied in the form of a finely dispersed polymer. Afterwards, the initial electrochromic compound is deaerated, thereby eliminating dissolved oxygen and air introduced by said finely dispersed polymer, and is used for filling the space between the electrodes.
Owner:AVELUM +1

Use of modified vasoactive intestinal peptides in the treatment of hypertension

The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and / or amelioration of hypertension are provided.
Owner:PHASEBIO PHARMA INC

Method for grinding spring with high quality and high efficiency

Disclosed is a method for grinding a spring with high quality and high efficiency, comprising the steps as follows: firstly, at least one of an upper grinding wheel (1) and a lower grinding wheel (2) is configured to comprise an inner grinding wheel (21) and an outer grinding wheel (24), wherein the inner grinding wheel (21) is fitted in the outer grinding wheel (24); the inner grinding wheel (21) or the outer grinding wheel (24) is driven by a transmission mechanism, the inner grinding wheel (21) and the outer grinding wheel (24) rotating in opposite directions; after a complete spring is fed to a space between the upper grinding wheel (1) and the lower grinding wheel (2), the complete spring is moved back and forth in the plane of the grinding wheels; and then the upper grinding wheel (1) is moved downwardly such that two end faces of the spring are ground by the grinding wheels, and when the height of the ground spring meets the requirement, the upper grinding wheel (1) is stopped moving downwardly and is returned to the original point later. Then, the ground spring movement is stopped and it is moved away from the space between the two grinding wheels, i.e., the complete spring is removed. In this way, the spring is ground in a revolving state, which can improve the yield and quality of ground springs, save energy and protect the environment, and result in a low cost of grinding, a simple structure, low cost for manufacturing parts, long persistence in precision of mechanisms, and good stability.
Owner:SHAOXING JIADU SPRING MACHINE

New sequence specific reagents targeting ccr5 in primary hematopoietic cells

The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.
Owner:ALBERT LUDWIGS UNIV FREIBURG +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products